Publications & Posters

Evaluation of Gohibic™ (vilobelimab) as a Cost-Effective Option to Treat Severely Ill Mechanically Ventilated Patients with COVID-19

Authors: Malone DC, Seheult R, Brixner D, Oderda G, Burnett BP, Biskupiak J
Publication details: AMCP Nexus Oct 14 - 17, 2024

Vilobelimab in Combination With Tocilizumab May Synergistically Improve Mortality in Critically Ill Covid-19 Patients: A Post-hoc Analysis of the Phase III PANAMO Study

Authors: Christian Sandrock MD, Alexander P.J. Vlaar MD, Endry H.T. Lim MD, Bruce P. Burnett PhD, Camilla Chong MD, Carina Zink, MSc, Robert Zerbib, MSc, Raymond M. Panas PhD, Renfeng Guo MD, Niels Riedemann MD, Diederik van de Beek MD
Publication details: CHEST 2024, October 6 - 9, 2024

Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, IHS4 and the newly introduced modified-HiSCR: a post hoc analysis of the Phase IIb SHINE study

Authors: Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek Szepietowski, Falk Bechara, Niels C. Riedemann, Camilla Chong, Hoda Tawfik
Publication details: European Academy of Dermatology & Venereology Congress, September 25-28, 2024

Vilobelimab in Combination With Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients: A Subgroup Analysis

Authors: Andrew F. Shorr MD, Alexander P.J. Vlaar MD, Endry H.T. Lim MD, Bruce P. Burnett PhD, Camilla Chong MD, Carina Zink, MSc, Robert Zerbib, MSc, Renfeng Guo MD, Niels Riedemann MD, Diederik van de Beek MD, Christian Sandrock MD
Publication details: American Journal of Respiratory and Critical Care Medicine 2024;209:A5511, May 26, 2024.

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Authors: Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, Leo M A Heunks, Bruno Mourvillier, Sanne de Bruin, Endry H T Lim, Matthijs C Brouwer, Pieter R Tuinman, José F K Saraiva, Gernot Marx, Suzana M Lobo, Rodrigo Boldo, Jesus A Simon-Campos, Alexander D Cornet, Anastasia Grebenyuk, Johannes M Engelbrecht, Murimisi Mukansi, Philippe G Jorens, Robert Zerbib, Simon Rückinger, Korinna Pilz, Renfeng Guo, Diederik van de Beek*, Niels C Riedemann*, on behalf of the PANAMO study group†
Publication details: Published Online September 7, 2022. doi: 10.1016/S2213-2600(22)00297-1

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Authors: Alexander P J Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd A M E G Timmermans, Ingeborg E van Zeggeren, Rutger Koning, Liora ter Horst, Esther B Bulle, Frank E H P van Baarle, Marcel C G van de Poll, E Marleen Kemper, Iwan C C van der Horst, Marcus J Schultz, Janneke Horn, Frederique Paulus, Lieuwe D Bos, W Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels C Riedemann, Diederik van de Beek
Publication details: Published Online September 28, 2020. doi: 10.1016/ S2665-9913(20)30341-6

Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?

Authors: Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ.
Publication details: Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16428. [Epub ahead of print]

Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application.

Authors: Sun S, Jiang Y, Wang R, Liu C, Liu X, Song N, Guo Y, Guo R, Du L, Jiang S, Li Y, Qiu Z, Zhao G, Zhou Y
Publication details: Crit Care Med. 2018 Jan 2. doi: 10.1097/CCM.0000000000002950. [Epub ahead of print]

IFX-1 blocking the anaphylatoxin C5a – an anti-inflammatory effect in patients with hidradenitis suppurativa.

Authors: Guo R, Habel M, Zenker O, Giamarellos-Bourboulis EJ, Riedemann NC
Publication details: 16th European Meeting on Complement in Human Disease (EMCHD2017), Copenhagen, Sep 2017

An open-label trial to assess the safety of IFX-1 in patients with hidradenitis suppurativa not eligible for Adalimumab.

Authors: Argyropoulou M, Kanni T, Zenker O, Riedemann NC, Giamarellos-Bourboulis EJ
Publication details: 26th European Academy of Dermatology and Venereology (EADV) Congress, Geneva, Sep 2017

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

Authors: Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R
Publication details: Clin Immunol. 2017 Jul;180:25-32. doi:10.1016/j.clim.2017.03.012

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors: Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M
Publication details: Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890